These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 16707463

  • 1. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 3. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

  • 4. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 5. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 6. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
    Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E.
    Drug Metab Dispos; 2004 Nov 01; 32(11):1230-8. PubMed ID: 15282212
    [Abstract] [Full Text] [Related]

  • 7. Safety and antitumor activity of recombinant soluble Apo2 ligand.
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.
    J Clin Invest; 1999 Jul 01; 104(2):155-62. PubMed ID: 10411544
    [Abstract] [Full Text] [Related]

  • 8. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF, Erff M, Ashkenazi A.
    Clin Cancer Res; 2001 May 01; 7(5):1362-9. PubMed ID: 11350907
    [Abstract] [Full Text] [Related]

  • 9. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA.
    J Pharmacol Exp Ther; 2001 Oct 01; 299(1):31-8. PubMed ID: 11561060
    [Abstract] [Full Text] [Related]

  • 10. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 11. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S.
    Cancer Res; 2006 Apr 15; 66(8):4309-18. PubMed ID: 16618756
    [Abstract] [Full Text] [Related]

  • 12. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 15; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 13. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y, Harada K, Ferdous T, Yoshida H.
    Anticancer Res; 2007 Jun 15; 27(4B):2365-75. PubMed ID: 17695527
    [Abstract] [Full Text] [Related]

  • 14. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S.
    Anticancer Res; 2006 Jun 15; 26(1A):259-65. PubMed ID: 16475706
    [Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT.
    Cancer Res; 2006 Apr 01; 66(7):3620-8. PubMed ID: 16585187
    [Abstract] [Full Text] [Related]

  • 16. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 17. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
    Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA.
    Immunol Invest; 2006 Feb 15; 35(3-4):279-96. PubMed ID: 16916755
    [Abstract] [Full Text] [Related]

  • 18. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.
    Clin Cancer Res; 2008 May 15; 14(10):3168-76. PubMed ID: 18483385
    [Abstract] [Full Text] [Related]

  • 19. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A.
    Br J Cancer; 2003 Jul 07; 89(1):206-14. PubMed ID: 12838325
    [Abstract] [Full Text] [Related]

  • 20. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX, Ong CN, Shen HM.
    Cancer Res; 2005 Sep 01; 65(17):7815-23. PubMed ID: 16140950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.